SEC Tracker
Get the app

Black Diamond Therapeutics BDTX

Black Diamond Therapeutics reported $10.01 million net loss for Q3 2026.

Black Diamond Therapeutics (BDTX) filed a 10-Q with the SEC on Nov 10, 2026, 6:32 am ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $0 for the three months ended Sep 30, 2026
  2. Net loss: $10.01 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $15.08 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Black Diamond Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$0$0—
Net income−$10.01M−$9.91M−1.1%
EPS−$0.17−$0.170%
Cash$15.08M$19.19M−21%

Data on this page was fetched . The filing on SEC.gov is the record.